TTTomoyoshi Takenaka

Tomoyoshi Takenaka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tomoyoshi Takenaka has a total of 84 co-authors. Here are the top co-authors by number of shared publications:

  • Tomoharu Yoshizumi

    Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

    27 shared publications
  • Mikihiro Kohno

    Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan

    21 shared publications
  • Fumihiko Kinoshita

    Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

    20 shared publications
  • Taichi Nagano

    Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

    19 shared publications
  • Kyoto Matsudo

    Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan

    17 shared publications
  • Mototsugu Shimokawa

    Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan

    15 shared publications

Latest Publications

  • Comparison of RATS Lobectomy and VATS Lobectomy for Early-stage Non-small Cell Lung Cancer

    by Tomoyoshi Takenaka, Takayuki Tokunaga, Fumihiko Kinoshita, Naoya Iwamoto, Taichi Matsubara, Kazuki Takada, Tomoharu Yoshizumi

    Robotic-assisted thoracoscopic surgery (RATS) for pulmonary resection of early-stage non-small cell lung cancer (NSCLC) has been increasingly adopted worldwide. To evaluate its safety and oncological efficacy, we compared the outcomes of RATS and video-assisted thoracoscopic surgery (VATS) lobectomy in patients with stage 0 or I NSCLC. Between August 2014 and December 2024, 330 patients with stage 0 or I NSCLC underwent pulmonary lobectomy via RATS (n=144) or VATS (n=186). RATS was performed using the da Vinci Xi system and VATS was performed using a conventional multiport technique. The perioperative and clinicopathological outcomes were retrospectively evaluated and analyzed after propensity score matching. The baseline characteristics were similar between the groups. The RATS group included more right upper lobectomies and fewer left upper lobectomies than the VATS group. Intraoperative blood loss was significantly lower in the RATS group. There were no significant differences in operative time, chest tube duration, postoperative complications, or length of hospital stay. Regarding lymph node (LN) dissection, the RATS group showed significantly higher numbers of dissected and total harvested LNs in the overall cohort. However, after propensity score matching, the LN yields were comparable between the groups. Both RATS and VATS lobectomies were safely performed for early-stage NSCLC. RATS achieved perioperative outcomes comparable to those achieved with VATS, with a reduced intraoperative blood loss. The lymph node harvest was similar after propensity score matching, suggesting that RATS provides oncological quality equivalent to that of VATS.

  • Open Access

    Identifying Key Variances in Clinical Pathways Associated With Prolonged Hospital Stays Using Machine Learning and ePath Real-World Data: Model Development and Validation Study

    by Saori Tou, Koutarou Matsumoto, Asato Hashinokuchi, Fumihiko Kinoshita, Yasunobu Nohara, Takanori Yamashita, Yoshifumi Wakata, Tomoyoshi Takenaka, Hidehisa Soejima, Tomoharu Yoshizumi, et al.

    Background: Prolonged hospital stays can lead to inefficiencies in health care delivery and unnecessary consumption of medical resources. Objective: This study aimed to identify key clinical variances associated with prolonged length of stay (PLOS) in clinical pathways using a machine learning model trained on real-world data from the ePath system. Methods: We analyzed data from 480 patients with lung cancer (age: mean 68.3, SD 11.2 years; n=263, 54.8% men) who underwent video-assisted thoracoscopic surgery at a university hospital between 2019 and 2023. PLOS was defined as a hospital stay exceeding 9 days after video-assisted thoracoscopic surgery. The variables collected between admission and 4 days after surgery were examined, and those that showed a significant association with PLOS in univariate analyses (P<.01) were selected as predictors. Predictive models were developed using sparse linear regression methods (Lasso, ridge, and elastic net) and decision tree ensembles (random forest and extreme gradient boosting). The data were divided into derivation (earlier study period) and testing (later period) cohorts for temporal validation. The model performance was assessed using the area under the receiver operating characteristic curve, Brier score, and calibration plots. Counterfactual analysis was used to identify key clinical factors influencing PLOS. Results: A 3D heatmap illustrated the temporal relationships between clinical factors and PLOS based on patient demographics, comorbidities, functional status, surgical details, care processes, medications, and variances recorded from admission to 4 days after surgery. Among the 5 algorithms evaluated, the ridge regression model demonstrated the best performance in terms of both discrimination and calibration. Specifically, it achieved area under the receiver operating characteristic curve values of 0.84 and 0.82 and Brier scores of 0.16 and 0.17 in the derivation and test cohorts, respectively. In the final model, a range of variables, including blood tests, care, patient background, procedures, and clinical variances, were associated with PLOS. Among these, particular emphasis was placed on clinical variances. Counterfactual analysis using the ridge regression model identified 6 key variables strongly linked to PLOS. In order of impact, these were abnormal respiratory sounds, postoperative fever, arrhythmia, impaired ambulation, complications after drain removal, and pulmonary air leaks. Conclusions: A machine learning–based model using ePath data effectively identified critical variances in the clinical pathways associated with PLOS. This automated tool may enhance clinical decision-making and improve patient management.


  • Clinical and biological impact of SNAT7 in lung adenocarcinoma: implications for prognosis and treatment

    by Asato Hashinokuchi, Naoki Haratake, Yuya Ono, Takumi Tomonaga, Giacomo Bassi, Kyoto Matsudo, Fumihiko Kinoshita, Taichi Matsubara, Mikihiro Kohno, Tomoyoshi Takenaka, et al.

    Glutamine metabolism plays a crucial role in cancer cell proliferation and modulates the tumour microenvironment. High expression of glutamine transporters is associated with poor prognosis in non-small cell lung cancer. SNAT7, encoded by SLC38A7, facilitates glutamine transport from lysosomes. However, its function and clinical significance in lung adenocarcinoma remain unclear. Immunohistochemistry (IHC) was performed with samples from 373 patients with completely resected lung adenocarcinoma, and the association between SNAT7 expression, clinicopathological features, and prognosis was examined. In addition, the biological findings were investigated in lung adenocarcinoma cell lines. Based on IHC analysis, we classified patients into high (n = 226, 60.6%) and low SNAT7 expression (n = 147, 39.4%) groups. High SNAT7 expression was substantially associated with male sex, smoking status, high maximum standardised uptake value, advanced pathological stage, and pleural, lymphatic, and vascular invasion, compared to low SNAT7 expression. Patients with high SNAT7 expression demonstrated substantially worse recurrence-free survival (RFS) and overall survival rates. Multivariable analysis revealed that high SNAT7 expression was an independent prognostic factor for RFS. In addition, SLC38A7 knockdown induced a decrease in proliferation with G1 arrest in lung adenocarcinoma cell lines. Our findings demonstrate that SNAT7 plays a pivotal role in promoting tumour malignancy and is significantly associated with poor prognosis in lung adenocarcinoma. These findings suggest that SNAT7 is a potential therapeutic target in lung adenocarcinoma.


  • CD155 expression and co-expression with PD-L1 are not associated with poor prognosis in patients with stage II and III lung adenocarcinoma undergoing surgical resection

    by Kyoto Matsudo, Kazuki Takada, Asato Hashinokuchi, Taichi Nagano, Fumihiko Kinoshita, Takaki Akamine, Mikihiro Kohno, Tomoyoshi Takenaka, Mototsugu Shimokawa, Yoshinao Oda, et al.

    Background CD155 has been identified as a ligand for T-cell immunoreceptor with Ig and ITIM domains. Herein, we investigated the relationship between the expressions of CD155 and programmed cell death-ligand 1 (PD-L1) and clinical outcomes in patients with surgically resected lung adenocarcinoma. Methods This study included 426 patients diagnosed with pathological stage (pStage) I–III lung adenocarcinoma who underwent surgery at Kyushu University Hospital. The number of tumor cells expressing CD155 and PD-L1 was assessed by immunohistochemistry, and the clinical significance of CD155 expression and CD155/PD-L1 co-expression in prognosis was investigated. Results Among the enrolled cohort, 320 (75.1%), 60 (14.1%), and 46 (10.8%) patients were diagnosed with pStage I, II, and III, respectively. Tissues from 112 patients (26.3%) were classified as having high CD155 expression. Co-expression of CD155 and PD-L1 was observed in 44 patients (10.3%). The High CD155 and CD155/PD-L1 co-expression groups had significantly poorer prognosis in pStage I–III lung adenocarcinoma. However, subgroup analysis revealed that the clinical significance of both CD155 expression and CD155/PD-L1 co-expression differed widely between patients with pStage I and II–III. Multivariate Cox proportional hazards regression analyses showed that high CD155 expression and CD155/PD-L1 co-expression were not independent poor prognostic factors in pStage II-III lung adenocarcinoma. Conclusion Our findings suggest that neither CD155 expression or CD155/PD-L1 co-expression are associated with poor prognosis in pStage II-III lung adenocarcinoma.


  • ASO Visual Abstract: DNA Polymerase Delta 2 Activates Cell Cycle in Lung Adenocarcinoma, Leading to High Malignancy and Poor Prognosis

    by Asato Hashinokuchi, Fumihiko Kinoshita, Makoto Iimori, Keisuke Kosai, Yuya Ono, Takumi Tomonaga, Bassi Giacomo, Kyoto Matsudo, Taichi Nagano, Takaki Akamine, et al.

  • Open Access

    CD155 expression and co-expression with PD-L1 are not associated with poor prognosis in patients with stage II and III lung adenocarcinoma undergoing surgical resection

    by Kyoto Matsudo, Kazuki Takada, Asato Hashinokuchi, Taichi Nagano, Fumihiko Kinoshita, Takaki Akamine, Mikihiro Kohno, Tomoyoshi Takenaka, Mototsugu Shimokawa, Yoshinao Oda, et al.

    Background: CD155 has been identified as a ligand for T-cell immunoreceptor with Ig and ITIM domains. Herein, we investigated the relationship between the expressions of CD155 and programmed cell death-ligand 1 (PD-L1) and clinical outcomes in patients with surgically resected lung adenocarcinoma. Methods: This study included 426 patients diagnosed with pathological stage (pStage) I to III lung adenocarcinoma who underwent surgery at Kyushu University Hospital. The number of tumor cells expressing CD155 and PD-L1 was assessed by immunohistochemistry, and the clinical significance of CD155 expression and CD155/PD-L1 co-expression in prognosis was investigated. Results: Among the enrolled cohort, 320 (75.1%), 60 (14.1%), and 46 (10.8%) patients were diagnosed with pStage I, II, and III, respectively. Tissues from 112 patients (26.3%) were classified as having high CD155 expression. Co-expression of CD155 and PD-L1 was observed in 44 patients (10.3%). The High CD155 and CD155/PD-L1 co-expression groups had significantly poorer prognosis in pStage I to III lung adenocarcinoma. However, subgroup analysis revealed that the clinical significance of both CD155 expression and CD155/PD-L1 co-expression differed widely between patients with pStage I and II-III. Multivariate Cox proportional hazards regression analyses showed that high CD155 expression and CD155/PD-L1 co-expression were not independent poor prognostic factors in pStage II-III lung adenocarcinoma. Conclusion: Our findings suggest that neither CD155 expression or CD155/PD-L1 co-expression are associated with poor prognosis in pStage II-III lung adenocarcinoma.

  • ASO Author Reflections: Clinical and Biological Significance of POLD2 in Lung Adenocarcinoma

    by Asato Hashinokuchi, Fumihiko Kinoshita, Tomoyoshi Takenaka, Tomoharu Yoshizumi

  • DNA Polymerase Delta 2 Activates Cell Cycle in Lung Adenocarcinoma, Leading to High Malignancy and Poor Prognosis

    by Asato Hashinokuchi, Fumihiko Kinoshita, Makoto Iimori, Keisuke Kosai, Yuya Ono, Takumi Tomonaga, Bassi Giacomo, Kyoto Matsudo, Taichi Nagano, Takaki Akamine, et al.

    DNA polymerase delta 2 (POLD2) plays a crucial role in DNA repair and replication. POLD2 is upregulated and related to poor prognosis in several types of c


  • ASO Visual Abstract: Significance of Tumor Microvasculature in the Tumor Microenvironment in Adenocarcinoma with EGFR Common Mutation

    by Kyoto Matsudo, Kazuki Takada, Asato Hashinokuchi, Taichi Nagano, Fumihiko Kinoshita, Takaki Akamine, Mikihiro Kohno, Tomoyoshi Takenaka, Mototsugu Shimokawa, Yoshinao Oda, et al.

  • Open Access

    Identifying Key Variances in Clinical Pathways Associated With Prolonged Hospital Stays Using Machine Learning and ePath Real-World Data: Model Development and Validation Study (Preprint)

    by Saori Tou, Koutarou Matsumoto, Asato Hashinokuchi, Fumihiko Kinoshita, Yasunobu Nohara, Takanori Yamashita, Yoshifumi Wakata, Tomoyoshi Takenaka, Hidehisa Soejima, Tomoharu Yoshizumi, et al.

    BACKGROUND Prolonged hospital stays can lead to inefficiencies in health care delivery and unnecessary consumption of medical resources. OBJECTIVE This study aimed to identify key clinical variances associated with prolonged length of stay (PLOS) in clinical pathways using a machine learning model trained on real-world data from the ePath system. METHODS We analyzed data from 480 patients with lung cancer (age: mean 68.3, SD 11.2 years; n=263, 54.8% men) who underwent video-assisted thoracoscopic surgery at a university hospital between 2019 and 2023. PLOS was defined as a hospital stay exceeding 9 days after video-assisted thoracoscopic surgery. The variables collected between admission and 4 days after surgery were examined, and those that showed a significant association with PLOS in univariate analyses (P<.01) were selected as predictors. Predictive models were developed using sparse linear regression methods (Lasso, ridge, and elastic net) and decision tree ensembles (random forest and extreme gradient boosting). The data were divided into derivation (earlier study period) and testing (later period) cohorts for temporal validation. The model performance was assessed using the area under the receiver operating characteristic curve, Brier score, and calibration plots. Counterfactual analysis was used to identify key clinical factors influencing PLOS. RESULTS A 3D heatmap illustrated the temporal relationships between clinical factors and PLOS based on patient demographics, comorbidities, functional status, surgical details, care processes, medications, and variances recorded from admission to 4 days after surgery. Among the 5 algorithms evaluated, the ridge regression model demonstrated the best performance in terms of both discrimination and calibration. Specifically, it achieved area under the receiver operating characteristic curve values of 0.84 and 0.82 and Brier scores of 0.16 and 0.17 in the derivation and test cohorts, respectively. In the final model, a range of variables, including blood tests, care, patient background, procedures, and clinical variances, were associated with PLOS. Among these, particular emphasis was placed on clinical variances. Counterfactual analysis using the ridge regression model identified 6 key variables strongly linked to PLOS. In order of impact, these were abnormal respiratory sounds, postoperative fever, arrhythmia, impaired ambulation, complications after drain removal, and pulmonary air leaks. CONCLUSIONS A machine learning–based model using ePath data effectively identified critical variances in the clinical pathways associated with PLOS. This automated tool may enhance clinical decision-making and improve patient management.